-+ 0.00%
-+ 0.00%
-+ 0.00%
Quoin says EMA grants orphan drug designation for QRX003 in peeling skin syndrome
Share
Listen to the news
Quoin says EMA grants orphan drug designation for QRX003 in peeling skin syndrome
  • Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome.
  • Status supports protocol guidance, fee reductions, EU grant access; provides 10-year EU market exclusivity upon approval.
  • First formal clinical trial in Peeling Skin Syndrome remains on track to start before year-end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140630PRIMZONEFULLFEED9845261) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending